Read more
Informationen zum Autor Kinam Park is Showalter Distinguished Professor of Biomedical Engineering & Professor of Pharmaceutics at Purdue University, USA. His research focuses in the areas of nano/micro particles, polymer micelles, drug-eluting stents, extracellular matrix, fast dissolving tablets, and smart hydrogels. Numerous potential new therapeutics are being researched by many different institutions and biomaterials technology is now being developed to target, treat and prevent cancer. This unique book discusses the role and potential Biomaterials have to treat this prevalent disease. Numerous potential new therapeutics are being researched by many different institutions and biomaterials technology is now being developed to target, treat and prevent cancer. This unique book discusses the role and potential Biomaterials have to treat this prevalent disease. Part 1 Fundamentals of biomaterials for cancer therapeutics: Introduction to biomaterials for cancer therapeutics; Cancer cell biology; Targeted drug delivery for cancer therapy. Part 2 Synthetic vaccines, proteins, and polymers for cancer therapeutics: Chemical synthesis of carbohydrate-based vaccines against cancers; Generating functional mutant proteins to create bioactive anti-cancer biopharmaceuticals; Polymer therapeutics for treating cancer. Part 3 Theranosis and drug delivery systems for cancer therapeutics: Nanotechnology for cancer screening and diagnosis; Nanomaterials for multimodal cancer cell imaging; Hybrid nanocrystal as a versatile platform for cancer theranostics; Embolisation devices for treating cancer tumours; Small Interfering RNAs (siRNAs) as Cancer Therapeutics; Reverse Engineering of Low Temperature Sensitive Liposome (LTSL) for treating cancer; Gold nanoparticles (GNPs) as multi-functional materials for treating cancer; Multifunctional nanosystems for cancer therapy. Part 4 Biomaterial therapeutics and cancer cell interaction: Biomaterial strategies to modulate cancer; 3D cancer models for evaluating chemotherapeutic efficacy; Nanotopography of biomaterials for controlling cancer cell function. ...
List of contents
Contributor contact details
Woodhead Publishing Series in Biomaterials
Preface
Chapter 1: Introduction to biomaterials for cancer therapeutics
Abstract:
1.1 Introduction
1.2 Biomaterials used in cancer therapeutics
1.3 Materials used in anticancer formulations
1.4 Conclusion and future trends
Chapter 2: Cancer cell biology
Abstract:
2.1 Introduction
2.2 Public perception and misunderstanding of cancer cell activity
2.3 The 'War on Cancer'
2.4 The genetic basis of cancer
2.5 Cancer interface with the environment
2.6 Cancer cells as moving targets
2.7 Conclusion and future trends
Chapter 3: Targeted drug delivery for cancer therapy
Abstract:
3.1 Introduction
3.2 Current paradigm
3.3 Challenges to current paradigm
3.4 Conclusion and future trends
Chapter 4: Chemical synthesis of carbohydrate-based vaccines against cancers
Abstract:
4.1 Introduction
4.2 Semi-synthetic vaccines
4.3 Fully synthetic vaccines
4.4 Conclusion and future trends
Chapter 5: Generating functional mutant proteins to create highly bioactive anticancer biopharmaceuticals
Abstract:
5.1 Introduction
5.2 Artificial proteins for cancer therapy
5.3 How to create functional mutant proteins as beneficial therapeutics
5.4 Mutant TNF? for cancer therapy
5.5 Conclusion and future trends
5.6 Sources of further information and advice
Chapter 6: Polymer therapeutics for treating cancer
Abstract:
6.1 Introduction
6.2 Polyamines and polyamine analogs
6.3 Polymeric P-glycoprotein (Pgp) inhibitors
6.4 Conclusion and future trends
6.5 Acknowledgment
Chapter 7: Nanotechnology for cancer screening and diagnosis
Abstract:
7.1 Introduction
7.2 Nanotechnology for cancer diagnosis
7.3 Nanotechnology-based biosensing platforms
7.4 Nanotechnology for biosensing - early detection of cancer
7.5 Nanotechnology for cancer imaging
7.6 Concerns with using nanomaterials
7.7 Conclusion and future trends
Chapter 8: Synergistically integrated nanomaterials for multimodal cancer cell imaging
Abstract:
8.1 Introduction
8.2 Nanomaterial-based multifunctional imaging probes
8.3 Nanoparticles with exogenous imaging ligands
8.4 Nanoparticles with endogenous contrast
8.5 Cocktail injection
8.6 Conclusion
Chapter 9: Hybrid nanocrystal as a versatile platform for cancer theranostics
Abstract:
9.1 Introduction
9.2 Imaging modality
9.3 Developing theranostic systems
9.4 Hybrid nanocrystal as theranostic platform
9.5 Conclusion
9.6 Acknowledgment
Chapter 10: Embolisation devices from biomedical polymers for intra-arterial occlusion drug delivery in the treatment of cancer
Abstract:
10.1 Introduction
10.2 Biomedical polymers and embolisation agents
10.3 Particulate embolisation agents
10.4 Drug-eluting embolisation beads
10.5 Polymer structure, form and property relationships
10.6 Experience with drug-eluting embolisation beads
10.7 Conclusions and future trends
10.8 Acknowledgement
Chapter 11: Small interfering RNAs (siRNAs) as cancer therapeutics
Abstract:
11.1 Introduction
11.2 Prerequisites for siRNAs cancer therapeutics
11.3 Delivery systems for anticancer siRNAs
11.4 Current challenges for clinical trials
11.5 Conclusion
11.6 Acknowledgement
Chapter 12: Reverse engineering of the low temperature-sensitive liposome (LTSL) for treating cancer
Abstract:
12.1 Introduction
12.2 What is reverse engineering?
12.3 Investigating the thermal-sensitive liposome's performance-in-
Report
"On the whole, the book is a combination of the fundamentals of cancer biology, guiding principles on the design of biomaterials and the clinical potential of these biomaterials, which is of interest to a broad audience involving chemists, biologist and material scientists." --Biomat.net, June 2014
"Intended for researchers, this collection introduces new methods for delivering drugs to cancer cells and tumors and innovative technologies for treating cancers with biomaterials. Needham .describes his low temperature-sensitive liposome (Thermodox) drug delivery system, which failed to meet its primary endpoint in a phase III trial of liver cancer." --ProtoView.com, February 2014
